References

Altshuler, L.L., Bauer, M., Frye, M.A., et al. (2001). Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry, 158,16171622.

Asnis, G.M., McGinn, L.K. & Sanderson, W.C. (1995). Atypical depression: Clinical aspects and noradrenergic function. Am J Psychiatry, 152, 31-36. Barbui, C. & Hotopf, M. (2001). Amitriptyline v. the rest: Still the leading antidepressant after

40 years of randomised controlled trials. Br J Psychiatry, 178, 129-144. Barrett-Connor, E., von Muhlen, D., Laughlin, G.A. & Kripke, A. (1999). Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo Study. J Am Geriatr Soc, 47, 685-691. Brody, A.L., Saxena, S., Stoessel, P., et al. (2001). Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings. Arch Gen Psychiatry, 58, 631-640. Cees de Groot, J.C., de Leeuw, F.-E., Oudkerk, M., Hofman, A., Jolles, J. & Breteler, M.M.B. (2000). Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry, 57, 1071-1076.

Cleare, A.J. & Bond, A.J. (1997). Does central serotonergic function correlate inversely with aggression? A study using d-fenfluramine in healthy subjects. Psychiatry Res, 69, 89-95. Coryell, W. & Sehlesser, M. (2001). The dexamethasone suppression test in suicide prediction. Am

J Psychiatry, 158, 748-753. Cravchik, A. & Goldman, D. (2000). Genetic diversity among human dopamine and serotonin receptors and transporters. Arch Gen Psychiatry, 57, 1105-1114. Delgado, P.L., Miller, H.L., Salomon, R.M., et al. (1999). Tryptophan depletion challenge in depressed patients treated with desipramine or fluoxetine: Implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry, 46, 212-220. Dorn, L.D., Burgess, E.S., Dubbert, B., et al. (1995). Psychopathology in patients with endogenous

Cushing's syndrome: 'Atypical' or melancholic features. Clin Endocrinol, 43, 433-442. Elliott, R., Rubinsztein, J.S., Sahakian, B.J., &Dolan, R.J. (2002). The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry, 59, 597-604. Fu, C.H., Reed, L.J., Meyerm, J.H., et al. (2001). Noradrenergic dysfunction in the prefrontal cortex in depression: An [15O] H2O PET study of the neuromodulatory effects of clonidine. Biol Psychiatry, 49, 317-325.

Fu, C.H.Y., Walsh, N.D. & Drevets, W.C. (2003). Neuroimaging studies of mood disorders. In: C.H.Y. Fu, T. Russell, C. Senior, D.R. Weinberger & R.M. Murray (Eds), neuroimaging in psychiatry. Martin Dunitz.

Gold, P.W., Licinio, J., Wong, M.L. & Chrousos, G.P. (1995). Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N YAcad Sci, 771, 716-729.

Harris, B., Othman, S., Davies, J.A., etal. (1992). Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ, 305, 152-156.

Heim, C., Newport, D.J., Heit, S., et al. (2000). Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA, 284, 592-597.

Heuser, I., Yassouridis, A. & Holsboer, F. (1994). The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. JPsychiatr Res, 28, 341-356.

Hirschfield, R.M.A. & Weissman, M.M. (2002). Risk factors for major depression and bipolar disorder. In: K.L. Davis, D. Charney, J.T. Coyle & C. Nemeroff (Eds), Neuropsychopharmacology. The Fifth Generation of Progress (pp. 1017-1026). Philadelphia: Lipincott Williams & Wilkins.

Janowsky, D.S. & Overstreet, D.H. (1995). The role of acetylcholine mechanisms in mood disorders. In: D.J. Kupfer & F.E. Bloom (Eds), Psychopharmacology: The Fourth Generation of Progress (pp. 945-956). New York: Raven Press.

Joffe, R. & Marriott, M. (2000). Thyroid hormone levels in recurrence of major depression. Am J Psychiatry, 157, 1689-1691.

Kendler, K.S., Eaves, L.J., Walters, E.E., Neale, M.C., Heath, A.C. & Kessler, R.C. (1996). The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry, 53, 391-399.

Kendler, K.S. & Karkowski Shuman, L. (1997). Stressful life events and genetic liability to major depression: Genetic control of exposure to the environment? Psychol Med, 27, 539-547.

Kendler, K.S., Thornton, L.M. & Gardner, C.O. (2000). Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the 'kindling' hypothesis. Am J Psychiatry, 157, 1243-1251.

Kendler, K.S., Thornton, L.M. & Gardner, C.O. (2001). Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry, 158, 582-586.

Kronfol, Z. & Remick, D.G. (2000). Cytokines and the brain: Implications for clinical psychiatry. Am J Psychiatry, 157, 683-694.

Lambert, G., Johansson, M.,Agren, H. & Friberg, P. (2000). Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: Evidence in support of the cate-cholamine hypothesis of mood disorders. Arch Gen Psychiatry, 57, 787-793.

Maes, M. & Meltzer, H. (1995). The serotonin hypothesis of major depression. In: F.E. Bloom & D.J. Kupfer (Eds), Psychopharmacology. Fourth Generation of Progress (pp. 933-944). New York: Raven Press.

Manji, H.K., Drevets, W.C. & Charney, D.S. (2001). The cellular neurobiology of depression. Nat Med, 7, 541-547.

Mann, J.J. (1995). Violence and aggression. In: F.E. Bloom & D.J. Kupfer (Eds), Psychopharmacology: The Fourth Generation of Progress (pp. 1919-1928). New York: Raven Press.

Martin, S.D., Martin, E., Rai, S.S., Richardson, M.A. & Royall, R. (2001). Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: Preliminary findings. Arch Gen Psychiatry, 58, 641-648.

Mayberg, H.S., Brannan, S.K. & Tekell, J.L., et al. (2000). Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response. Biol Psychiatry, 48, 830-843.

Moreno, F.A., Heninger, G.R., McGahueya, C.A. & Delgado, P.L. (2000). Tryptophan depletion and risk of depression relapse: A prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry, 48, 327-329.

Murphy, B.E. (1997). Antiglucocorticoid therapies in major depression: A review. Psychoneuroen-docrinology, 22, S125-132.

Nemeroff, C. (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Mol Psychiatry, 1, 336-342.

O'Flynn, K. & Dinan, T.G. (1993). Baclofen-induced growth hormone release in major depression: Relationship to dexamethasone suppression test result. Am J Psychiatry, 150, 1728-1730.

Owens, M.J. & Nemeroff, C.B. (1994). Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. Clin Chem, 40, 288-295.

Reilly, J.G., McTavish, S.F.B. & Young, A.H. (1997). Rapid depletion of plasma tryptophan: A review of studies and experimental methodology. J Psychopharmacol, 11, 381-392.

Sargent, P.A., Kjaer, K.H., Bench, C.J., et al. (2000). Brain serotoninlA receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry, 57, 174-180.

Schatzberg, A.F., Garlow, S.J. & Nemeroff, C.B. (2002). Molecular and cellular mechanisms in depression. In: K.L. Davis, D. Charney, J.T. Coyle & C. Nemeroff (Eds), Neuropsychopharmacology. The Fifth Generation of Progress (pp. 1039-1050). Philadelphia: Lipincott Williams & Wilkins.

Sheline, Y.I. & Minyun, M.A. (2002). Structural and functional imaging of affective disorders. In: K.L. Davis, D. Charney, J.T. Coyle & C. Nemeroff (Eds), Neuropsychopharmacology. The Fifth Generation of Progress (pp. 1065-1080). Philadelphia: Lipincott Williams & Wilkins.

Smith, D., Dempster, C., Glanville, J., Freemantle, N. & Anderson, I. (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry, 180, 396-404.

Smith, K.A., Morris, J.S., Friston, K.J., Cowen, P.J. & Dolan, R.J. (1999). Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. Br J Psychiatry, 174, 525-529.

Sullivan, P.F., Kessler, R.C. & Kendler, K.S. (1998). Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. Am J Psychiatry, 155, 1398-1406.

Thase, M.E., Dube, S., Bowler, K., et al. (1996). Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients. Am J Psychiatry, 153, 886-891.

Thase, M.E., Simons, A.D. & Reynolds, C.F.D. (1993). Psychobiological correlates of poor response to cognitive behavior therapy: Potential indications for antidepressant pharmacotherapy. Psy-chopharmacol Bull, 29, 293-301.

Van London, L., Goekoop, J.G., Zwinderman, A.H., Lanswer, J.B.K., Wiegent, V.M. & De Wied, D. (1998). Neuropsychological performance and plasma cortisol arginine vasopressin and oxytocin in patients with major depression. Psychol Med, 28, 275-284.

Wheeler Vega, J., Mortimer, A. & Tyson, P.J. (2000). Somatic treatment of psychotic depression: Review and recommendations for practice. J Clin Psychopharmacol, 20, 504-519.

Wolkowitz, O.M., Reus, V.I., Keebler, A., et al. (1999). Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry, 156, 646-649.

Young, A.H., Gallagher, P. & Porter, R.J. (2002). Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry, 159, 1237-1239.

Defeat Depression

Defeat Depression

Learning About How To Defeat Depression Can Have Amazing Benefits For Your Life And Success! Discover ways to cope with depression and melancholic tendencies! Depression and anxiety particularly have become so prevalent that it’s exceedingly common for individuals to be taking medication for one or even both of these mood disorders.

Get My Free Ebook


Post a comment